Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
1.
Clin Chest Med ; 43(4): 697-716, 2022 12.
Artigo em Inglês | MEDLINE | ID: mdl-36344075

RESUMO

Nontuberculous mycobacteria (NTM) are important pathogens, with a longitudinal prevalence of up to 20% within the cystic fibrosis (CF) population. Diagnosis of NTM pulmonary disease in people with CF (pwCF) is challenging, as a majority have NTM infection that is transient or indolent, without evidence of clinical consequence. In addition, the radiographic and clinical manifestations of chronic coinfections with typical CF pathogens can overlap those of NTM, making diagnosis difficult. Comprehensive care of pwCF must be optimized to assess the true clinical impact of NTM and to improve response to treatment. Treatment requires prolonged, multidrug therapy that varies depending on NTM species, resistance pattern, and extent of disease. With a widespread use of highly effective modulator therapy (HEMT), clinical signs and symptoms of NTM disease may be less apparent, and sensitivity of sputum cultures further reduced. The development of a disease-specific approach to the diagnosis and treatment of NTM infection in pwCF is a research priority, as a lifelong strategy is needed for this high-risk population.


Assuntos
Fibrose Cística , Infecções por Mycobacterium não Tuberculosas , Humanos , Fibrose Cística/complicações , Quimioterapia Combinada , Hansenostáticos/uso terapêutico , Micobactérias não Tuberculosas , Infecções por Mycobacterium não Tuberculosas/diagnóstico , Infecções por Mycobacterium não Tuberculosas/tratamento farmacológico , Infecções por Mycobacterium não Tuberculosas/epidemiologia
2.
Front Cell Infect Microbiol ; 10: 598938, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-33262957

RESUMO

Microbial communities infiltrate the respiratory tract of cystic fibrosis patients, where chronic colonization and infection lead to clinical decline. This report aims to provide an overview of the diversity of bacterial and fungal species from the airway secretion of three young CF patients with severe pulmonary disease. The bacterial and fungal microbiomes were investigated by culture isolation, metataxonomics, and metagenomics shotgun. Virulence factors and antibiotic resistance genes were also explored. A. fumigatus was isolated from cultures and identified in high incidence from patient sputum samples. Candida albicans, Penicillium sp., Hanseniaspora sp., Torulaspora delbrueckii, and Talaromyces amestolkiae were isolated sporadically. Metataxonomics and metagenomics detected fungal reads (Saccharomyces cerevisiae, A. fumigatus, and Schizophyllum sp.) in one sputum sample. The main pathogenic bacteria identified were Staphylococcus aureus, Pseudomonas aeruginosa, Burkholderia cepacia complex, and Achromobacter xylosoxidans. The canonical core CF microbiome is composed of species from the genera Streptococcus, Neisseria, Rothia, Prevotella, and Haemophilus. Thus, the airways of the three young CF patients presented dominant bacterial genera and interindividual variability in microbial community composition and diversity. Additionally, a wide diversity of virulence factors and antibiotic resistance genes were identified in the CF lung microbiomes, which may be linked to the clinical condition of the CF patients. Understanding the microbial community is crucial to improve therapy because it may have the opposite effect, restructuring the pathogenic microbiota. Future studies focusing on the influence of fungi on bacterial diversity and microbial interactions in CF microbiomes will be welcome to fulfill this huge gap of fungal influence on CF physiopathology.


Assuntos
Fibrose Cística , Microbiota , Brasil , Fibrose Cística/complicações , Humanos , Pulmão , Escarro , Talaromyces
4.
Proc Natl Acad Sci U S A ; 103(22): 8487-92, 2006 May 30.
Artigo em Inglês | MEDLINE | ID: mdl-16687478

RESUMO

In many human infections, hosts and pathogens coexist for years or decades. Important examples include HIV, herpes viruses, tuberculosis, leprosy, and malaria. With the exception of intensively studied viral infections such as HIV/AIDs, little is known about the extent to which the clonal expansion that occurs during long-term infection by pathogens involves important genetic adaptations. We report here a detailed, whole-genome analysis of one such infection, that of a cystic fibrosis (CF) patient by the opportunistic bacterial pathogen Pseudomonas aeruginosa. The bacteria underwent numerous genetic adaptations during 8 years of infection, as evidenced by a positive-selection signal across the genome and an overwhelming signal in specific genes, several of which are mutated during the course of most CF infections. Of particular interest is our finding that virulence factors that are required for the initiation of acute infections are often selected against during chronic infections. It is apparent that the genotypes of the P. aeruginosa strains present in advanced CF infections differ systematically from those of "wild-type" P. aeruginosa and that these differences may offer new opportunities for treatment of this chronic disease.


Assuntos
Adaptação Fisiológica/genética , Fibrose Cística/complicações , Fibrose Cística/microbiologia , Infecções por Pseudomonas/complicações , Infecções por Pseudomonas/microbiologia , Pseudomonas aeruginosa/genética , Pseudomonas aeruginosa/fisiologia , Proteínas de Bactérias/genética , Doença Crônica , Fibrose Cística/patologia , Proteínas de Ligação a DNA/genética , Genoma Bacteriano/genética , Humanos , Dados de Sequência Molecular , Mutação/genética , Infecções por Pseudomonas/patologia , Pseudomonas aeruginosa/isolamento & purificação , Seleção Genética , Fatores de Tempo , Transativadores/genética
5.
Int J Antimicrob Agents ; 12 Suppl 2: S11-5, 1999 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-10528782

RESUMO

Fusidic acid, both systemic and topical, has been used for a wide variety of less common infections. Efficacy for oral fusidic acid has been demonstrated in the treatment of Clostridium difficile colitis and in staphylococcal infections in patients with cystic fibrosis. Topical fusidic acid gel is also effective in bacterial conjunctivitis and other minor external eye infections, and may be effective in reducing bacterial flora in the conjunctival sac prior to eye surgery. Studies suggest a potential role for fusidic acid in neurosurgical prophylaxis, as adjunctive therapy in bacterial endophthalmitis and Legionella pneumonia, and in leprosy. Topical fusidic acid has no effect in the treatment of chlamydial conjunctivitis or the prevention of staphylococcal infections in patients on continuous ambulatory peritoneal dialysis.


Assuntos
Antibacterianos/uso terapêutico , Ácido Fusídico/uso terapêutico , Infecções/tratamento farmacológico , Antibacterianos/administração & dosagem , Clostridioides difficile , Conjuntivite/tratamento farmacológico , Fibrose Cística/complicações , Fibrose Cística/tratamento farmacológico , Endoftalmite/tratamento farmacológico , Enterocolite Pseudomembranosa/tratamento farmacológico , Ácido Fusídico/administração & dosagem , Humanos , Controle de Infecções , Hanseníase Virchowiana/tratamento farmacológico , Neurocirurgia , Soluções Oftálmicas , Diálise Peritoneal Ambulatorial Contínua/efeitos adversos , Pneumonia/tratamento farmacológico , Infecções Estafilocócicas/tratamento farmacológico , Infecções Estafilocócicas/etiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA